本帖最后由 老马 于 2013-3-13 13:43 编辑
* {% Z* W; E- s& h5 w* E2 S4 f' b( x$ c- i
健择(吉西他滨)+顺铂+阿瓦斯汀
; d1 r; C" l( P y& C0 S5 P Gemzar +Cisplatin + Avastin+ W( T O6 \( E( G
http://annonc.oxfordjournals.org/content/21/9/1804.full
- }, U$ V$ Q, i; Z \Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
6 _& Z9 R! v- APatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 9 j" d+ n7 z: M# E: }3 {8 [* K
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ( `* G6 e7 o; I: X# d' I2 x
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 227)
2 G& u! a1 {! r9 e
华为网盘附件:' x1 d+ }8 ?3 a- f- I6 J G2 ~' L
【华为网盘】ava.JPG* o# {+ x/ X. i- k5 u% a/ I
|